Shots:
- The P-III (METIS) trial assessed TTFields therapy + best supportive care (BSC) (n=149) vs BSC (n=149) in 298 adults with 1-10 newly diagnosed brain metastases from NSCLC following stereotactic radiosurgery; median TTFields use was 67% over 16wks.
- Trial met its 1EP, with a 28% lower risk of intracranial progression, extending median time to 15 vs 7.5mos. & consistently lowering progression rates of 13.6% vs 22.1%, 33.7% vs 46.4%, 46.9% vs 59.4% & 53.6% vs 65.2% at 2, 6, 12, & 24mos., respectively
- No significant differences were seen in 2EPs incl. neurocognitive failure, OS, or MRI-assessed brain lesions, but TTDP trended longer (18.6 vs 11.3mos.), with greater benefit in ICI-treated pts (n=118) & improved deterioration-free survival; data published in The Red Journal &presented at ASTRO’25
Ref: Novocure | Image: Novocure | Press Release
Related News:- Novocure Reports MHLW’s Approval of Optune Lua for NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
